Alessandro Sessa

9PUBLICATIONS
66CO-AUTHORS
Haematological tumoursEpigenetics (incl. genome methylation and epigenomics)Molecular targetsNeurogeneticsNeural engineering
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Apr 23, 2026
MeCP2 gene dosage-dependent neurodevelopmentally restricted defects arise by aberrant activation of cell fate-determining bivalent genes.

|Jan 09, 2024
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis.

Ilaria Crespiatico, Mattia Zaghi, Cristina Mastini

|Jun 03, 2023
Balanced SET levels favor the correct enhancer repertoire during cell fate acquisition.

Mattia Zaghi, Federica Banfi, Luca Massimino

|Jan 08, 2023
CRISPR/Cas9-Induced Inactivation of the Autism-Risk Gene setd5 Leads to Social Impairments in Zebrafish.

Chiara Gabellini, Cecilia Pucci, Chiara De Cesari

|Aug 03, 2022
A SOX2-engineered epigenetic silencer factor represses the glioblastoma genetic program and restrains tumor development.

Valerio Benedetti, Federica Banfi, Mattia Zaghi

|Nov 27, 2021
Rare Does Not Mean Worthless: How Rare Diseases Have Shaped Neurodevelopment Research in the NGS Era.

Mattia Zaghi, Federica Banfi, Edoardo Bellini

Pageof 2

Frequent Collaborators

6 joint publications

Vania Broccoli

4 joint publications

Edoardo Bellini

3 joint publications

Rocco Piazza

2 joint publications

Luca Massimino